Table 2. Response rates per RECIST 1.1 criteria in patients treated with nab-paclitaxel plus S-1 (ITT population).

Tumor response, No. (%)	Best response by investigator review	Best response by independent review
Complete response#	2 (3.3)	1 (1.7)
Partial response#	28 (46.7)	29 (48.3)
Stable disease	19 (31.7)	13 (21.7)
Progressive disease	6 (10.0)	12 (20.0)
Not assessable*	5 (8.3)	5 (8.3)
Objective response rate	30 (50.0)	30 (50.0)
Disease control rate	49 (81.7)	43 (71.7)

Abbreviation: ITT, Intention-to-Treat.

^# Complete response and partial response were all confirmed at least 4 weeks apart according to RECIST 1.1 criteria.

^* Five patients had no response evaluation due to lost follow-up after 2 cycles of treatment in 4 patients and one had worsening Eastern Cooperative Oncology Group performance status.